IP Verse

Method Of Treatment - EP2976101

The patent EP2976101 was granted to Glaxosmithkline on Aug 19, 2020. The application was originally filed on Mar 17, 2014 under application number EP14711232A. The patent is currently recorded with a legal status of "Revoked".

EP2976101

GLAXOSMITHKLINE
Application Number
EP14711232A
Filing Date
Mar 17, 2014
Status
Revoked
Feb 2, 2024
Grant Date
Aug 19, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

SANOFI PASTEURMay 18, 2021WILDINGADMISSIBLE

Patent Citations (6) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
EXAMINATIONUS2008193476
EXAMINATIONUS2008305127
INTERNATIONAL-SEARCH-REPORTAU2012203419
OPPOSITIONWO2007000314
OPPOSITIONWO2007111940
OPPOSITIONWO9942130

Non-Patent Literature (NPL) Citations (40) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
EXAMINATION- Anonymous, "Recommendation of the Advisory Committee on Immunization Practices (ACIP) for Use of Quadrivalent Meningococcal Conjugate Vaccine (MenACWY-D) Among Children Aged 9 Through 23 Months at Increased Risk for Invasive Meningococcal Disease", (20111014), URL: https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6040a4.htm, (20191105), XP055639261-
EXAMINATION- Kristina A. Bryant, "Immunogenicity and Safety of H influenzae Type b- N meningitidis C/Y Conjugate Vaccine in Infants", (20110529), pages e1375 - 85, URL: https://pediatrics.aappublications.org/content/127/6/e1375, (20191105), XP055639247-
EXAMINATION- Me Pichichero, "Meningococcal conjugate vaccine in adolescents and children.", Clin Pediatr (Phila)., (20050701), vol. 44, no. 6, pages 479 - 489, XP055464391-
EXAMINATION- MARKUS KNUF ET AL, "An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered withhexa is immunogenic, with an acceptable safety profile in 1223-month-old children", VACCINE, ELSEVIER, AMSTERDAM, NL, vol. 29, no. 25, doi:10.1016/J.VACCINE.2011.03.009, ISSN 0264-410X, (20110303), pages 4264 - 4273, (20110309), XP028217535
EXAMINATION- Gary S. Marshall ET AL, "IMMUNE RESPONSE AND ONE-YEAR ANTIBODY PERSISTENCE AFTER A FOURTH DOSE OF A NOVEL HAEMOPHILUS INFLUENZAE TYPE B AND NEISSERIA MENINGITIDIS SEROGROUPS C AND Y-TETANUS TOXOID CONJUGATE VACCINE (HibMenCY) AT 12 TO 15 MONTHS OF AGE :", PEDIATRIC INFECTIOUS DISEASE JOURNAL., US, (20100501), vol. 29, no. 5, doi:10.1097/INF.0b013e3181cdd379, ISSN 0891-3668, pages 469 - 471, XP055639251
EXAMINATION- Gary S. Marshall ET AL, "Co-administration of a novel Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine does not interfere with the immune response to antigens contained in infant vaccines routinely used in the United States", HUMAN VACCINES, US, (20110201), vol. 7, no. 2, doi:10.4161/hv.7.2.14170, ISSN 1554-8600, pages 258 - 264, XP055639233
OPPOSITION- Anonymous, "284 Menactra", Sanofi Pasteur Datasheet, (20111130), vol. V0-11, no. L5917, pages 1 - 36, XP055954833-
OPPOSITION- Anonymous, "Adipic acid dihydrazide", Wikipedia, the free encyclopedia, (20211214), Wikipedia, the free encyclopedia, URL: https://en.wikipedia.org/wiki/Adipic_acid_dihydrazide, (20231219), XP093113510-
OPPOSITION- Anonymous, "Advisory conmittee on immunization practice (ACIP) votes to recommend routine use of combined tetanus, diphteria and Pertussis (Tdap) vaccines for adolescents", Webarchive, (20051029), pages 1 - 2, XP055954866-
OPPOSITION- Anonymous, "Assessment report : Nimenrix", (20110301), pages 1 - 84, URL: https://www.ema.europa.eu/en/documents/assessment-report/nimenrix-epar-public-assessment-report_en.pdf, (20191111), XP055641291-
OPPOSITION- Anonymous, "Commision implementing decision of 20.04.2012 granting marketing authorisation under regulation (EC) N0 726/2004 of the European Parliament and of the council for NIMENRIX-Meningococcal Group A, C, W-135 and Y conjugate vaccine, a medicinal product for human use", European Commision decision, (20120420), vol. 20, pages 1 - 58, XP055954810-
OPPOSITION- Anonymous, "Commission decision of 31.8.2010", European Commission decision, (20100831), vol. 8, pages 1 - 72, XP055954844-
OPPOSITION- Anonymous, "Factsheet Haemophilus influenzae type b (Hib) and meningococcal serogroup C (MenC) vaccines for children", NHS, (20060801), pages 1 - 20, XP093096607-
OPPOSITION- Anonymous ., "GlaxoSmithKline receives European authorisation for Nimenrix", EPR, (20120427), pages 1 - 4, XP055954816-
OPPOSITION- Anonymous, " Glossary of Common Site Terms", ClinicalTrials.gov, (20210506), pages 1 - 19, XP055954792-
OPPOSITION- Anonymous, " Glossary of Common Site Terms COVID 19 information", ClinicalTrials.gov, (20210506), pages 1 - 19, ClinicalTrials.gov, (20220825), XP055954747-
OPPOSITION- Anonymous ., "GSK receives FDA approval for MenHibrix ", EPR, (20120614), pages 1 - 5, XP055954805-
OPPOSITION- Anonymous, "Hexavalent vaccine", (20230508), pages 1 - 4, Wikipedia , URL: https://en.wikipedia.org/w/index.php?title=Hexavalent_vaccine&oldid=1153747448, (20231030), XP093096231-
OPPOSITION- Anonymous, "HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use MENHIBRIX ", Datasheet, (20120101), pages 1 - 14, XP055954804-
OPPOSITION- Anonymous, "History of Changes for Study: NCT00614614 Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014", ClinicalTrials.gov, (20111122), pages 1 - 7, XP055954838-
OPPOSITION- Anonymous, "History of Changes for Study: NCT00667602 ,Safety and Immunogenicity Evaluation After One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants and Toddlers ", ClinicalTrials.gov archive, (20130903), pages 1 - 49, ClinicalTrials.gov archive, (20220825), XP055954744-
OPPOSITION- Anonymous, "History of Changes for Study: NCT01659996 Study of Menactra in Healthy Subjects at 9 Months and Concomitantly With Pentacel at 15 to 18 Months of Age", ClinicalTrials.gov, (20130205), pages 1 - 6, XP055954857-
OPPOSITION- Anonymous, "Immuno safety of GSK Vaccine 134612 given at age of 12-15 months 15-18 months post-priming with GSK Vaccine 792014", ClinicalTrials.gov, (20180921), pages 1 - 14, XP055954749-
OPPOSITION- Anonymous, " Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014 ", ClinicalTrials.gov, (20180921), vol. NCT00614614, pages 1 - 14, XP055954801-
OPPOSITION- Anonymous, "Meningococcal groups C and Y and Haemophilus b Tetanus Toxoid conjugate vaccine", Vaccines, Blood & Biologics, (20120622), pages 1 - 1, XP055954803-
OPPOSITION- Anonymous, "Recommended Childhood and Adolescent Immunization Schedule ---United States 2005", MMWR, (20050107), vol. 53, no. 51, pages Q1 - Q3, XP055954823-
OPPOSITION- Anonymous, "Result summaries : Meningococcal Serogroups A, C, W-135 and Y-Tetanus Toxoid conjugate vaccine", Webarchive.org, (20120527), pages 1 - 1, Webarchive.org, (20220825), XP055954819-
OPPOSITION- Anonymous, "Routine childhood immunisations from November 2010", NHS, (20101101), pages 1 - 1, XP093096612-
OPPOSITION- Anonymous ., "Sanofi Pasteur announces FDA approval of Menactra", EPR, (20110422), pages 1 - 4, XP055954847-
OPPOSITION- Anonymous, "Summary of Product Characteristics", (20090603), pages 1 - 8, EMC, URL: https://web.archive.org/web/20101117174728/http://www.medicines.org.uk:80/emc/medicine/17189/SPC/Menitorix, (20231031), XP093096585-
OPPOSITION- Anonymous, "Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: An open, randomized controlled trial", Vaccine, (20110406), pages 1 - 11, XP055954855-
OPPOSITION- Knuf, M. ; Kieninger-Baum, D. ; Habermehl, P. ; Muttonen, P. ; Maurer, H. ; Vink, P. ; Poolman, J. ; Boutriau, D., "A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children", Vaccine, AMSTERDAM, NL , (20100108), vol. 28, no. 3, ISSN 0264-410X, pages 744 - 753, XP026793745-
OPPOSITION- Matthew D Snape, Perrett Kp, Ford Kj, John Tm, Pace D, Yu Lm, Langley Jm, Mcneil S, Dull Pm, Ceddia F, Anemona A, Halperin Sa, Dobson S, Pollard Aj., "Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial.", JAMA - Journal of the American Medical Association, (20080101), pages 173 - 184, JAMA - Journal of the American Medical Association, (20130129), XP055051640-
OPPOSITION- Vliegenthart, J.F.G., "Carbohydrate based vaccines", FEBS Letters, NL , (20060522), vol. 580, no. 12, doi:10.1016/j.febslet.2006.03.053, ISSN 0014-5793, pages 2945 - 2950, XP025171199
OPPOSITION- Broker, M. ; Dull, P.M. ; Rappuoli, R. ; Costantino, P., "Chemistry of a new investigational quadrivalent meningococcal conjugate vaccine that is immunogenic at all ages", Vaccine, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20090918), vol. 27, no. 41, doi:10.1016/j.vaccine.2009.07.036, ISSN 0264-410X, pages 5574 - 5580, XP026502234
OPPOSITION- Markus Knuf; Anna Pantazi-Chatzikonstantinou; Ulrich Pfletschinger; Irmingard Tichmann-Schumann; Hartwig Maurer; Lothar Maurer; Thomas Fischbach; Henrike Zinke; Heidemarie Pankow-Culot; Vassiliki Papaevangelou; Veronique Bianco; Marie Van der Wielen; Jacqueline M. Miller;, "An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered withhexa is immunogenic, with an acceptable safety profile in 1223-month-old children", Vaccine, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20110303), vol. 29, no. 25, doi:10.1016/j.vaccine.2011.03.009, ISSN 0264-410X, pages 4264 - 4273, XP028217535
OPPOSITION- Trotter Caroline L., Chandra Manosree, Cano Rosa, Larrauri Amparo, Ramsay Mary E., Brehony Carina, Jolley Keith A., Maiden Martin C. J., Heuberger Sigrid, Frosch Matthias, "A surveillance network for meningococcal disease in Europe", FEMS Microbiology Reviews, (20070101), vol. 31, no. 1, doi:10.1111/j.1574-6976.2006.00060.x, pages 27 - 36, XP093096182
OPPOSITION- Esposito Susanna, Principi Nicola, "Differences in vaccinations in European Union", Human Vaccines, US , (20080101), vol. 4, no. 4, doi:10.4161/hv.4.4.5587, ISSN 1554-8600, pages 313 - 315, XP093096230
OPPOSITION- Gasparini R, Panatto D., "Meningococcal glycoconjugate vaccines", HUMAN VACCINES, LANDES BIOSCIENCE, GEORGETOWN, TX, US, US , (20110201), vol. 7, no. 2, doi:10.4161/hv.7.2.13717, ISSN 1554-8600, pages 170 - 182, XP002725640
OPPOSITION- Gary S. Marshall, Colin D. Marchant, Mark Blatter, Leonard R. Friedland, Emmanuel Aris, Jacqueline M. Miller, "Co-administration of a novel Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine does not interfere with the immune response to antigens contained in infant vaccines routinely used in the United States", HUMAN VACCINES, LANDES BIOSCIENCE, GEORGETOWN, TX, US, US , (20110201), vol. 7, no. 2, doi:10.4161/hv.7.2.14170, ISSN 1554-8600, pages 258 - 264, XP055639233

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents